•  

News - TIAP

FedDev Ontario Funding Support – Portfolio Investments

On October 9, 2020, the Honourable Mélanie Joly, Minister of Economic Development and Official Languages and Minister responsible for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) announced a FedDev Ontario contribution of $6.5 million to Toronto Innovation Acceleration Partners. Read more here: https://bit.ly/3nBEXDR  Under this Agreement TIAP has to date made the following investments in our portfolio startup companies: Bitnobi - $15,000, April 1, 2019 Bright Angel Therapeutics - $30,000, August 2, 2019 and $70,000, December 23, 2020 Hypercare Inc. - $100,000, August 12, ... Read more

Notch Therapeutics Raises $85M Series A Financing

TIAP portfolio company Notch Therapeutics has announced one of the largest Series A financing rounds in the history of Canadian biotech. We are proud to say that we were there from the start in 2017 when TIAP received the technology disclosure from Dr. Zuniga-Pflucker via our Member, Sunnybrook Health Sciences Centre, and then again when we teamed up with CCRM and Dr. Peter Zandstra of University of Toronto, another one of our Members. TIAP was an early seed investor and acknowledges ... Read more

Webinar February 24, 2021: Adventures in Drug Hunting – Identify and Advance Your Drug-Like Molecule

On February 24, 2021 TIAP hosted a LAB150 webinar entitled Adventures in Drug Hunting: Identify and Advance Your Drug-Like Molecule.  Click to listen to a recording of the webinar: https://zoom.us/rec/share/VllBSf8Jw4_O2mz70LGTuYQwTJb1MZ5ksnYaiY6YrsPRZI8Xfsx0B9yNRl-Q98gc._i9OthG2tcQC58eP. Access Passcode: VF2k!vXj Here is the full description of the webinar content: In the second of three webinars in the LAB150 series, we turn to the initial stages of identifying and developing a therapeutic compound. This follows our previous discussion of target identification and validation. Now that you have a validated therapeutic target, how do you go about ... Read more

TIAP & Amgen Co-funds transformative projects to support new venture development

December 8, 2020 TIAP announces co-funding of transformative projects with Amgen to support new venture development Toronto Innovation Acceleration Partners (TIAP) is excited to announce co-investments made with a key strategic partner, Amgen Inc., into three translational life sciences projects from its members: University of Toronto, University Health Network (UHN) and The Hospital for Sick Children (SickKids). The TIAP-Amgen partnership, formalized in 2019, has an objective to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations ... Read more

Webinar: Staying on Target – How to Determine if Your Research Program is Ready for Drug Delivery

Staying on Target: How to Determine if Your Research Program is Ready for Drug Discovery LAB150 Presents: A 3-part Webinar Series on Drug Discovery and Development November 17, 2020 - 12-1:30 PM ET Click here to hear a recording of the webinar: http://bit.ly/2O5dDR4  In the first of three webinars in the LAB150 series on drug discovery and development, we focus on the initial steps on the long path of bringing a new drug to market and to patients in need. Specifically, we examine approaches to target ... Read more

Funding for Zucara Therapeutics Expansion Into ZT-01 Development Program to Type 2 Diabetes

November 2, 2020: Zucara Therapeutics Inc., a diabetes life sciences startup funded by TIAP and adMare BioInnovations,  announced today that it has received funding from NRC IRAP and MITAS for its expansion into the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”). Red more here: https://bit.ly/34QRAn6 Read more

Bristol Myers Squibb Enters Agreement to Acquire Forbius

TIAP portfolio company Forbius announced on August 24, 2020 that they have entered into an acquisition deal with Bristol Myers Squibb. BMS is adding lead TGF-beta asset to its portfolio. TIAP was one of the earliest investors and partners with Forbius in 2011/12. This is a big win for Forbius CEO Dr. Tikhomirov and the Canadian research and innovation community. Forbius (formerly Formation Biologics) is a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic ... Read more

TIAP CEO appointed to Govt of Canada’s COVID-19 Task Force

TIAP's President & CEO, Parimal Nathwani, is appointed to the Government of Canada's COVID-19 Core Task Force to advise on funding of new and potential therapies for COVID-19: https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/hn01780.html    Read more

LAB150 launches new immuno-oncology project from Sunnybrook Research Institute

Toronto, Ontario, June 04, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project aimed at developing a novel therapeutic agent for immuno-oncology. The research for the promising new approach comes from Dr. Jean Gariépy and his lab at Sunnybrook Research Institute, a TIAP Member institution. The last several years has seen the introduction of a new blockbuster class of drugs for treating cancers – specifically, the immune checkpoint inhibitors (ICIs). These drugs act ... Read more

Funding for Sinai Health Netherton Syndrome project from partners AmorChem and Evotec

TORONTO, May 12, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide. The project was initiated in partnership with a group of scientists from Sinai Health’s Lunenfeld-Tanenbaum Research Institute (LTRI) in Toronto, Canada and focuses on a specific group of enzymes called tissue kallikreins. These proteins ... Read more
Page 1 of 3812345...102030...Last »